Expect Extraordinary
Exeltis is an independent, family-owned women’s healthcare company passionately committed to serving patients, making a contribution to society and caring for the well being of our employees.
Expect even more from us
Our commitment to excellence fuels our passion for innovation, our production, and the delivery of products that improve the quality of life of millions of women worldwide. Continuously learning, growing and adapting to meet emerging healthcare needs, we expect nothing but extraordinary from ourselves.
The numbers speak for themselves
40
Years of Experience
15
Production facilities
40
Countries
300
Products
6,000
Employees
10
R & D Centers
Mission
Inspired by the strength, courage, and hope of women around the world, our global mission is to improve the health of women by providing access to innovative, effective, first-class therapeutic solutions. Driven by our mission and our hope for a healthier future, we’re working continuously to innovate and explore the awesome potential of science to develop groundbreaking medicines for women worldwide.
Company Culture
EXPLORE OUR CULTURE
Wondering who we are? We’re dreamers, visionaries and scientists. We’re movers and shakers, working together to make our vision of a healthier future a reality.
We are guided by our philosophy — “Work As You Live”, channeling the values we cherish outside of work into our working life. We strive to be better every day, taking care of each other and treating each other with respect. We live with integrity, accepting each other’s differences and embracing change.
We’re autonomous and efficient, yet passionate about growing as a team, offering opinions with freedom and humility, supporting each other through difficult times, and celebrating each other’s accomplishments. We believe in ourselves and we believe in each other. Working as we live makes our Exeltis family strong, connected, and a truly rewarding place to work.
Grounded in innovation and collaboration, our culture reflects our commitment to our people and our dedication to our mission. Curious, compassionate, creative, and encouraging, we honor each other and respect each other’s contributions.
When you join the Exeltis family, you’ll find yourself collaborating with extraordinary colleagues from all walks of life, and you’ll be supported with opportunities for growth and learning at every stage of your career.
Company History
Exeltis is part of the global InSud Pharma group, a family-owned pharmaceutical company with over 40 years of experience.
Everett Laboratories Inc. (Now Exeltis USA, Inc.) was founded in 1971 and entered the women’s health market in the mid 1990’s, with a focus on pre-natal supplementation. Since then, Exeltis USA, Inc. has brought other important women’s health products to market, building a strong reputation with the healthcare professionals specializing in Women’s Health.
Exeltis is a global organization which operates through a network of more than 40 subsidiaries, employing close to 4,000 professionals across over 40 countries.
Exeltis aims to make a real difference in any corner of the world. With nearly 6,000 passionate employees spread across 40 countries we strive to help 2 billion people who lack access to cost effective therapeutics.
R&D and Clinical Trial Capabilities
Our Research and Development capabilities are laser-focused on women’s health, and our most recent product, Slynd, is the result of more than a decade of hard work, dedication, and commitment. Exeltis is proud to have brought this much-needed new birth control brand, to market for women worldwide.
The Slynd project started 10 years ago, with the goal of delivering on an unmet need recognized by various health authorities and by the scientific community: creating an estrogen-free contraceptive with the same efficacy as combined oral contraceptives, but better safety for certain populations, including women over 35, smokers, and obese women who have a higher risk of cardiovascular effects.
Over the past decade, our Clinical Trial department recruited approximately 3,000 women into 20 of our global clinical studies including phases I, II and III, totaling about 20,000 female cycles of drug exposure. We estimate that over 90% of reproductive-aged women are candidates for Slynd, which is a far greater percentage than for any other oral contraceptive.
Approved by the US Food and Drug Administration (FDA) in May 2019, Slynd is an innovative, estrogen-free, progestin-only pill (POP) offering a unique 24 active + 4 placebo dosing regimen and 24 hour missed pill window. Slynd contains the active ingredient drospirenone and has been proven to offer similar efficacy to existing combined oral contraceptives, with fewer side effects and a better bleeding profile than the currently available progestin-only pills.
Now millions of women can have an excellent choice for effective oral contraception without the risks of estrogen.
